American Journal of Cardiology
Volume 106, Issue 3 , Pages 354-359, 1 August 2010

Comparison of Atorvastatin 80 mg/day Versus Simvastatin 20 to 40 mg/day on Frequency of Cardiovascular Events Late (Five Years) After Acute Myocardial Infarction (from the Incremental Decrease in End Points Through Aggressive Lipid Lowering [IDEAL] Trial)

  • Terje R. Pedersen, MD, PhD

      Affiliations

    • Center for Preventive Medicine, Oslo University Hospital, and University of Oslo, Norway
    • Corresponding Author InformationCorresponding author: fax: +47-22-60-19-00
    • ,
  • Nilo B. Cater, MD

      Affiliations

    • Pfizer, Inc., New York, New York
    • ,
  • Ole Faergeman, MD, DMSc

      Affiliations

    • Department of Medicine–Cardiology A, Århus University Hospital, Århus, Denmark
    • ,
  • John J.P. Kastelein, MD, PhD

      Affiliations

    • Academic Hospital Amsterdam, Amsterdam, The Netherlands
    • ,
  • Anders G. Olsson, MD, PhD

      Affiliations

    • Department of Internal Medicine, University Hospital, Linköping, Sweden
    • ,
  • Matti J. Tikkanen, MD, PhD

      Affiliations

    • Medical Clinic, Helsinki University Hospital and Folkhälsan Research Center, Helsinki, Finland
    • ,
  • Ingar Holme, PhD

      Affiliations

    • Center for Preventive Medicine, Oslo University Hospital, and University of Oslo, Norway
    • ,
  • Mogens Lytken Larsen, MD, DMSc

      Affiliations

    • Department of Medicine–Cardiology A, Århus University Hospital, Århus, Denmark
    • ,
  • Christina Lindahl, MD

      Affiliations

    • Pfizer Sweden, Täby, Sweden
    • ,
  • Michael Szarek, PhD

      Affiliations

    • Pfizer, Inc., New York, New York

Received 22 December 2009; received in revised form 15 March 2010; accepted 15 March 2010.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 The IDEAL study was funded by Pfizer, Inc., New York, New York.

PII: S0002-9149(10)00782-4

doi:10.1016/j.amjcard.2010.03.033

American Journal of Cardiology
Volume 106, Issue 3 , Pages 354-359, 1 August 2010

Article Tools

* Image Usage & Resolution